2008
DOI: 10.1164/rccm.200705-678oc
|View full text |Cite
|
Sign up to set email alerts
|

Serum Amyloid A Is a Biomarker of Acute Exacerbations of Chronic Obstructive Pulmonary Disease

Abstract: SAA is a novel blood biomarker of AECOPD that is more sensitive than CRP alone or in combination with dyspnea. SAA may offer new insights into the pathogenesis of AECOPD.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

5
163
2
7

Year Published

2009
2009
2021
2021

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 224 publications
(179 citation statements)
references
References 67 publications
5
163
2
7
Order By: Relevance
“…However, we were able to demonstrate that serum-SAA was related to the degree of CVD-burden and that a strength of this study was the fact that none of our subjects were on lipid-lowering medication, especially statins, which are known to lower SAA[41], thus removing any confounding influence that these drugs may have displayed on our findings. Our findings are consistent with previous studies that have proposed serum-SAA as sensitive biomarker to illustrate increased inflammation [3,[27][28]. In the circulation, SAA rapidly associates with HDL, where it renders this lipoprotein dysfunctional with numerous proinflammatory actions [9][10][11], which include reduced antioxidant capacity [15] and reduced RCT capabilities [10].…”
Section: Discussionsupporting
confidence: 92%
“…However, we were able to demonstrate that serum-SAA was related to the degree of CVD-burden and that a strength of this study was the fact that none of our subjects were on lipid-lowering medication, especially statins, which are known to lower SAA[41], thus removing any confounding influence that these drugs may have displayed on our findings. Our findings are consistent with previous studies that have proposed serum-SAA as sensitive biomarker to illustrate increased inflammation [3,[27][28]. In the circulation, SAA rapidly associates with HDL, where it renders this lipoprotein dysfunctional with numerous proinflammatory actions [9][10][11], which include reduced antioxidant capacity [15] and reduced RCT capabilities [10].…”
Section: Discussionsupporting
confidence: 92%
“…These results indicate that the measurement of APP such as SAA may prove valuable in assessing the severity of respiratory infection in pigs, and may be of supportive value in the clinical evaluation of animals and in the selection of more appropriate treatment. In agreement with the present results, the positive relationship between SAA and disease severity was also reported previously in pigs, humans, and other species (4,9,15,28,29).…”
Section: Discussionsupporting
confidence: 94%
“…30 SAA is regarded as a biomarker of COPD and inflammatory joint disease that is more sensitive than CRP. 13,31 Accumulating evidence suggests that SAA is a biomarker and a mediator of atherosclerosis: Increased SAA levels have been identified as a predictor of coronary artery disease and cardiovascular outcome, and serve as an indicator for the extent of the disease. 14 Furthermore, elevated systemic SAA levels are a hallmark of individuals who suffer from obesity and diabetes, 32,33 and these inflammatory diseases are linked to an increased risk of developing atherosclerosis and heart disease.…”
Section: Discussionmentioning
confidence: 99%
“…10 Further suggested functions of SAA comprise chemotaxis for monocytes and neutrophils, the promotion of pro-inflammatory cytokine expression, and the prolongation of the lifespan of neutrophils through an antiapoptotic effect. 11,12 Elevated SAA levels are implicated in several chronic inflammatory diseases, such as amyloidosis, atherosclerosis, rheumatoid arthritis and chronic obstructive pulmonary disease (COPD), 12,13 suggesting that SAA may have an active role in these diseases. Similar to CRP, SAA is a biomarker for the prediction of cardiovascular diseases.…”
Section: Introductionmentioning
confidence: 99%